Aethl Bio locks in manufacturing deal with Pure Source

Aethl Bio signed a definitive manufacturing and supply agreement with The Pure Source on June 16, 2026, formalizing a long-term production partnership as the Pittsburgh biomaterials company moves toward commercialization. The deal gives Aethl Bio access to FDA-registered, cGMP-certified manufacturing capacity while the company keeps ownership of its intellectual property and formulations. Why it matters: - The agreement gives Aethl Bio a commercial-scale manufacturing base as the company prepares to move products toward market. - The deal reduces operational risk by pairing Aethl Bio’s proprietary product plans with Pure Source’s FDA-registered, cGMP-certified manufacturing infrastructure. - Aethl Bio keeps full ownership of its intellectual property, formulations, and product specifications. What happened: - Aethl Bio, Inc. announced on June 16, 2026, that it executed a definitive Manufacturing and Supply Agreement with The Pure Source, LLC. - The Pure Source is an FDA-registered contract manufacturer headquartered in Doral, Florida. - The agreement formalizes the relationship the two companies outlined in their April 2026 memorandum of understanding. - The deal covers long-term, commercial-scale manufacturing of Aethl Bio’s proprietary products. The details: - The MSA pairs Aethl Bio’s proprietary formulations and product vision with Pure Source’s manufacturing systems, quality controls, and operational capacity. - Aethl Bio said the agreement establishes the production foundation it will rely on as it scales toward commercialization. - The agreement includes companion quality and supply arrangements that support the long-term partnership. - Pure Source is an FDA-registered drug establishment and cGMP-certified contract manufacturer founded in 1995. - Pure Source specializes in topical pharmaceuticals, cosmetics, and dietary supplements. - The company provides formulation, manufacturing, and supply chain services for emerging and established brands. - Aethl Bio is a Pittsburgh-based biomaterials company focused on wound care and wellness applications. - Aethl Bio is advancing products built on its Hydro-Activated Supersaturation platform across skin health, recovery, and wellness. Between the lines: - The move shifts the companies from a preliminary framework to a more durable operating relationship. - For a company preparing for commercialization, a definitive manufacturing agreement can signal greater readiness for scale and regulatory execution. - The language around quality systems, specifications, and manufacturing controls suggests the partnership is designed to support repeatable production rather than one-off batches. - Both companies framed the deal as a foundation for growth, which points to a broader push beyond development-stage activity. What’s next: - Aethl Bio will use the manufacturing relationship as it continues its path toward commercialization. - Pure Source will provide manufacturing, regulatory, and quality support under the long-term arrangement. - The companies positioned the agreement as the base for Aethl Bio’s next phase of growth. The bottom line: - Aethl Bio has turned a March-style partnership concept into a formal manufacturing deal that should help it scale from development toward market launch.